Image may be NSFW.
Clik here to view.
Clik here to view.
Roth starts EnteroMedics at buy
Roth Capital Partners has initiated coverage of EnteroMedics (NASDAQ:ETRM) with a “buy” rating and $5 price target. The closed at $2.39 on Wednesday. EnteroMedics has developed the Maestro Rechargeable...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Roth ups EnteroMedics price target
Roth Capital Partners has raised its price target for “buy-rated” EnteroMedics (NASDAQ:ETRM) to $3 from $2 after the company announced positive 18-month data for its ReCharge pivotal trial that...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Roth ups EnteroMedics price target to $5
Roth Capital Partners has raised its price target for “buy-rated” EnteroMedics (NASDAQ:ETRM) to $5 from $3 after the FDA’s Gastroenterology-Urology Device Advisory Panel voted that the benefits of the...
View Article
